Adagio Medical Reports Positive vCLAS Results for VT
LOS ANGELES, April 2026 Adagio Medical announced positive pivotal clinical results for its vCLAS® Ventricular Ablation System, highlighting a...
Alzheimer’s Disease Autoimmune Disease Bio-Pharma biologics biopharma biopharma innovation Biotechnology cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development EMA FDA fda approval FDA clearance GCP Gene Therapy GMP Immuno-Oncology immunology Immunotherapy Medical Devices MedTech medtech innovation Monoclonal Antibody Oncology oncology innovation Orphan Drug orphan drug designation patient access Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory approval regulatory compliance targeted therapy
LOS ANGELES, April 2026 Adagio Medical announced positive pivotal clinical results for its vCLAS® Ventricular Ablation System, highlighting a...
LAGUNA HILLS, Calif., March 19, 2026 Adagio Medical Holdings, Inc. announced successful outcomes from Expanded Access Program (EAP) cases...
